Chimerix (CMRX) Competitors

Akero Therapeutics (NASDAQ:AKRO) and Chimerix (NASDAQ:CMRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends.

Do insiders and institutionals believe in AKRO or CMRX?

45.4% of Chimerix shares are owned by institutional investors. 7.9% of Akero Therapeutics shares are owned by company insiders. Comparatively, 13.1% of Chimerix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community believe in AKRO or CMRX?

Chimerix received 279 more outperform votes than Akero Therapeutics when rated by MarketBeat users. However, 65.36% of users gave Akero Therapeutics an outperform vote while only 62.96% of users gave Chimerix an outperform vote.

Company	Underperform	Outperform
Akero Therapeutics	Outperform Votes 117 65.36%	Underperform Votes 62 34.64%
Chimerix	Outperform Votes 396 62.96%	Underperform Votes 233 37.04%

Does the media favor AKRO or CMRX?

In the previous week, Akero Therapeutics had 7 more articles in the media than Chimerix. MarketBeat recorded 12 mentions for Akero Therapeutics and 5 mentions for Chimerix. Chimerix's average media sentiment score of 1.27 beat Akero Therapeutics' score of 1.21 indicating that Chimerix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akero Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chimerix	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate AKRO or CMRX?

Akero Therapeutics currently has a consensus target price of $76.29, indicating a potential upside of 67.26%. Chimerix has a consensus target price of $8.53, indicating a potential downside of 0.08%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Akero Therapeutics is more favorable than Chimerix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Chimerix	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more volatility & risk, AKRO or CMRX?

Akero Therapeutics has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500. Comparatively, Chimerix has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500.

Is AKRO or CMRX more profitable?

Akero Therapeutics' return on equity of -32.46% beat Chimerix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akero Therapeutics	N/A	-32.46%	-29.83%
Chimerix	N/A	-50.78%	-44.94%

Which has higher valuation & earnings, AKRO or CMRX?

Chimerix has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akero Therapeutics	N/A	N/A	-$151.76M	-$3.75	-12.16
Chimerix	$212K	3,778.71	-$82.10M	-$0.99	-8.63

Summary

Chimerix beats Akero Therapeutics on 9 of the 16 factors compared between the two stocks.